January 7, 2011

HELIX BIOPHARMA CORP. FILES IND FOR A U.S. PHASE I CLINICAL STUDY OF ITS CANCER DRUG CANDIDATE L-DOS47 (PDF)

AURORA, Ontario, January 7, 2011 – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), a developer of
biopharmaceutical drug candidates for the prevention and treatment of cancer, today announced that it has filed an
investigational new drug (“IND”) application with the United States Food and Drug Administration (“FDA”) seeking approval
to perform its planned Phase I clinical safety and tolerability study of its cancer drug candidate L-DOS47.